Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
View: Text | PDF
Research Article Inflammation Oncology

Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers

  • Text
  • PDF
Abstract

Carcinomas are common in humans but rare among closely related “great apes.” Plausible explanations, including human-specific genomic alterations affecting the biology of sialic acids, are proposed, but causality remains unproven. Here, an integrated evolutionary genetics-phenome-transcriptome approach studied the role of SIGLEC12 gene (encoding Siglec-XII) in epithelial transformation and cancer. Exogenous expression of the protein in cell lines and genetically engineered mice recapitulated approximately 30% of the human population in whom the protein is expressed in a form that cannot bind ligand because of a fixed, homozygous, human-universal missense mutation. Siglec-XII–null cells/mice recapitulated the remaining approximately 70% of the human population in whom an additional polymorphic frameshift mutation eliminates the entire protein. Siglec-XII expression drove several pro-oncogenic phenotypes in cell lines and increased tumor burden in mice challenged with chemical carcinogen and inflammation. Transcriptomic studies yielded a 29-gene signature of Siglec-XII–positive disease and when used as a computational tool for navigating human data sets, pinpointed with surprising precision that SIGLEC12 expression (model) recapitulates a very specific type of colorectal carcinomas (disease) that is associated with mismatch-repair defects and inflammation, disproportionately affects European Americans, and carries a favorable prognosis. They revealed a hitherto-unknown evolutionary genetic mechanism for an ethnic/environmental predisposition of carcinogenesis.

Authors

Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh

×

Figure 3

Creation and validation of a transgenic knockin SIGLEC12 murine model that expresses Siglec-XII in the small and large intestine.

Options: View larger image (or click on image) Download as PowerPoint
Creation and validation of a transgenic knockin SIGLEC12 murine model th...
(A) Schematic displays the cloning strategy for creation of the SIGLEC12–knockin mice (wild-type mice do not harbor a SIGLEC12 gene). Tissue-specific Cre-driver mice express a tamoxifen-inducible system of estrogen receptor fused to Cre (Cre-ERT). In the absence of tamoxifen (T), Hsp90 binds to Cre-ERT and maintains its cytoplasmic retention. Nuclear translocation of Cre-ERT by tamoxifen. In the nucleus, Cre-ERT recognizes loxP sites and allows tissue-specific expression of Siglec-XII. (B) An overview of experimental design for the induction of Siglec-XII expression by serial administration of tamoxifen on 5 consecutive days, followed by harvesting of tissues to confirm early (day 12) and sustained (day 87) expression of Siglec-XII. (C) Western blot for Siglec-XII and β-actin on transgenic mouse and control tissues at day 12 after induction using tamoxifen. (D) Expression of Siglec-XII in mouse tissue evaluated by immunohistochemistry at day 12 after induction using tamoxifen. Scale bar: 100 μm. See also Supplemental Figure 2A (for immunoblots) and Supplemental Figure 2B (for immunohistochemistry) on samples at day 87 after induction.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts